News

Is Abeona Therapeutics' Zevaskyn Worth $3.1m Per Treatment, Or Will Krystal Biotech Remain The Market Leader?
Krystal's Vyjuvek innovative gene therapy leads DEB treatment, overshadowing Abeona's Zevaskyn. Check out the comparison ...